Author | Juergen Wolf, MD | OncLive

Author | Juergen Wolf, MD

Articles

Dr. Wolf on the Design of GEOMETRY mono-1 Trial in METex14-Mutated NSCLC

June 20, 2020

Video

Jüergen Wolf, MD, discusses the design and rationale of the phase 2 GEOMETRY mono-1 study with capmatinib (Tabrecta) in METex14-mutated or high MET amplified, advanced non–small cell lung cancer.

Dr. Wolf on Updated Findings With Capmatinib in METex14-Mutant NSCLC

June 04, 2020

Video

Jüergen Wolf, MD, discusses data the phase 2 GEOMETRY mono-1 trial with capmatinib (Tabrecta) in patients with METex14-mutated or high MET amplified advanced non–small cell lung cancer.

Dr. Wolf on GEOMETRY mono-1 Phase II Trial With Capmatinib in NSCLC

August 29, 2019

Video

Jüergen Wolf, MD, medical director, Center for Integrated Oncology, professor, Interdisciplinary Translational Oncology at University Hospital of Cologne, discusses the primary efficacy data of the phase II GEOMETRY mono-1 trial exploring the MET inhibitor capmatinib as treatment for patients with non-small cell lung cancer and exon-14 mutations.

Dr. Wolf Discusses the GEOMETRY Study in MET+ NSCLC

December 13, 2018

Video

Juergen Wolf, MD, medical director, Center for Integrated Oncology, University Hospital of Cologne, Köln Bonn, Köln, Germany, discusses the GEOMETRY study in patients with MET-positive non–small cell lung cancer (NSCLC).

x